Myasthenia Gravis: A Case Study Focusing on Comprehensive Nursing Management
DOI:
https://doi.org/10.31305/rrijm.2025.v10.n7.015Keywords:
MG (Myasthenia Gravis), Nursing management, Patient Family Education, Muscle weaknessAbstract
Myasthenia Gravis (MG) is a rare, chronic autoimmune neuromuscular disorder that causes weakness in the skeletal muscles. Skeletal muscles are responsible to control voluntary actions like speaking, swallowing, breathing, and the movement of limbs.MG is caused by antibody- and cell-mediated destruction of acetylcholine receptors, leading to the blockade of neuromuscular transmission. This disruption can result in episodic skeletal muscle weakness and easy fatigability. The antibodies either block, alter, or destroy the acetylcholine receptors at the neuromuscular junction, thereby preventing proper muscle contraction. The classical presentation of patient with difficulty in breathing, increased cough and secretion. Usually, the associated symptoms are poor voluntary muscle movements involves in speaking, swallowing, breathing, and moving limbs. A 70-year-old male presented with complaint of difficulty in breathing, swallowing and slurred speech, right eye ptosis for two days and also had productive cough for 10 days. A significant past history revealed of diabetes, hypertension, and chronic kidney disease. Physical examination revealed right eye ptosis, neck weakness and difficulty in holding his neck. There was no significant family history of autoimmune diseases and without any preceding trauma or significant stressor. Radiological investigations were found to be non-significant except few laboratory investigations such as Total leucocyte count (TC), C-Reactive Protein (CRP) and Procalcitonin (PCT). The patient was treated with cholinergic agonists, corticosteroids, monoclonal antibody, Intravenous Immunoglobulin (IVIg) therapy and antimicrobial therapy which eventually helped to improve significantly. The patient got discharged in stable condition. He returned to his previous baseline lifestyle without any complications.
References
Carr, A.S., Cardwell, C.R., McCarron, P.O. et al. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10, 46 (2010). https://doi.org/10.1186/1471-2377-10-46
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3. PMID: 26376969.
Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010 Jul;17(7):893-902. doi: 10.1111/j.1468-1331.2010.03019.x. Epub 2010 Apr 12. PMID: 20402760.
Gilhus, Nils Erik, et al. “Myasthenia gravis—autoantibody characteristics and their implications for therapy.” Nature Reviews Neurology, vol. 12, no. 5, May 2016, pp. 259+. Gale Academic OneFile, link.gale.com/apps/doc/A453916627/AONE?u=anon~ec89bbb6&sid=googleScholar&xid=487531d1. Accessed 27 June 2025.
Tombak A, Uçar MA, Akdeniz A, Yilmaz A, Kaleagası H, Sungur MA, Tiftik EN. Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases. Indian J Hematol Blood Transfus. 2017 Mar;33(1):97-105. doi: 10.1007/s12288-016-0661-3. Epub 2016 Feb 22. PMID: 28194064; PMCID: PMC5280851.
Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis. 2011;2011:847393. doi: 10.4061/2011/847393. Epub 2011 Oct 5. PMID: 22007295; PMCID: PMC3189457.
Collongues N, Casez O, Lacour A, Tranchant C, Vermersch P, de Seze J, Lebrun C. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve. 2012 Nov;46(5):687-91. doi: 10.1002/mus.23412. Epub 2012 Aug 31. PMID: 22941747.
Blum S, Gillis D, Brown H, Boyle R, Henderson R, Heyworth-Smith D, Hogan P, Kubler P, Lander C, Limberg N, Pillans P, Prain K, Staples C, Walsh M, McCombe P, Wong R. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):659-63. doi: 10.1136/jnnp.2010.220475. Epub 2010 Nov 11. PMID: 21071753.
Kondo K. Optimal therapy for thymoma. J Med Invest. 2008 Feb;55(1-2):17-28. doi: 10.2152/jmi.55.17. PMID: 18319541.
Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis. 2011;2011:847393. doi: 10.4061/2011/847393. Epub 2011 Oct 5. PMID: 22007295; PMCID: PMC3189457.
Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010 Jul;17(7):893-902. doi: 10.1111/j.1468-1331.2010.03019.x. Epub 2010 Apr 12. PMID: 20402760.
Payus AO, Leow Wen Hsiang J, Leong JQ, Ibrahim A, Raymond AA. Myasthenic Crisis as the First Presentation of Myasthenia Gravis: A Case Report. Am J Case Rep. 2021 Jan 20;22:e928419. doi: 10.12659/AJCR.928419. PMID: 33468985; PMCID: PMC7823149.
Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004 Mar;24(1):17-20. doi: 10.1055/s-2004-829593. PMID: 15229788.
Aarli JA. Myasthenia gravis in the elderly: Is it different? Ann N Y Acad Sci. 2008;1132:238-43. doi: 10.1196/annals.1405.040. PMID: 18567874.
Gilhus NE. Physical training and exercise in myasthenia gravis. Neuromuscul Disord. 2021 Mar;31(3):169-173. doi: 10.1016/j.nmd.2020.12.004. Epub 2020 Dec 24. PMID: 33461846.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open access article under the CC BY-NC-ND license Creative Commons Attribution-Noncommercial 4.0 International (CC BY-NC 4.0).